Ingredient Safety

Browse Ingredient Safety Content

parent and baby feet

Press Releases and Statements

CHPA Statement on Pediatrics Article Showing Decrease in Unsupervised Medication Exposures in Young Children

CHPA released the following statement in response to an article in Pediatrics, the official journal of the American Academy of Pediatrics, which reported a decline in emergency department visits for unsupervised medication exposures in young children.

Sep 8, 2015

Orange CHPA logo on dark blue background

Press Releases and Statements

CHPA Applauds House Introduction of DXM Abuse Prevention Act

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act of 2015 (H.R. 3250), introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson (R-OH) and Doris Matsui (D-CA).

Jul 28, 2015

Orange CHPA logo on dark blue background

Press Releases and Statements

CHPA Statement on FDA Drug Safety Communication on NSAIDs

The Consumer Healthcare Products Association today issued the following statement in response to the Food and Drug Administration’s Drug Safety Communication on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).

Jul 10, 2015

Clear gel capsules in a pile

Submission

Letter to Attorney General Regarding Tainted Dietary Supplements

May 19, 2015

Orange CHPA logo on dark blue background

Press Releases and Statements

CHPA Thanks Governor Bill Haslam for Signing Legislation

Apr 9, 2015

Colleagues Examining Data on a computer

Submission

Comments to FDA: Drug Watch for Emerging Drug Safety Information

CHPA has supported and continues to support the timely provision of complete and accurate product information to healthcare professionals and patients in an easily accessible format, and commends the Agency for considering new approaches to disseminating emerging drug safety-related data.

Aug 8, 2005

Orange CHPA logo on dark blue background

Submission

CHPA Presentation at FDA Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Regarding NSAIDs

In considering the safety of NSAIDs, the use of OTC NSAIDs should be clearly distinguished from long-term prescription NSAID use. OTC medicines have a different overall benefit-to-risk equation and a wider margin of safety than prescription NSAIDs.

Feb 17, 2005

Clear gel capsules in a pile

Submission

Comments to IOM: Scientific Framework for Safety Evaluations of Dietary Supplements

CHPA charged IOM to develop a proposed framework for categorizing and prioritizing DS ingredients based on safety issues, describe a process for developing a system of scientific reviews for evaluating the safety of DS ingredients, and develop at least six scientific reviews as prototypes for the system.

Oct 11, 2001

scientist with long dark hair in a lab facing away

Submission

Letter to FDA: Benzoyl Peroxide Safety Studies

Enclosed for DA review is an "Update on Safety Studies with Benzoyl Peroxide" submitted by the NDMA Benzoyl Peroxide Study Group.

Feb 26, 1999

scientist with long dark hair in a lab facing away
Guideline for the Stability Testing of Nonprescription (OTC) Drug Products Not Regulated by an NDA/ANDA

The objective of this guideline is to define the minimum stability data package to support the commercial distribution of OTC monograph drug products in the United States per climatic zone.

Filter Results